Evaluation of an Optimized Injection System for Retinal Gene Therapy in Human Patients

Human Gene Therapy Methods

Volumn 27, Issue 4, 2016, Pages 150-158

  Fischer, M Dominik ^a,b,c   Hickey, Doron G ^a   Singh, Mandeep S ^a,b,d   MacLaren, Robert E ^a,b,d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b OXFORD EYE HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

POLITEF; VIRUS VECTOR;

ARTICLE; EQUIPMENT DESIGN; EVALUATION STUDY; FLOW RATE; GENE DELIVERY SYSTEM; GENE THERAPY; GENOME; HUMAN; INJECTION; PRESSURE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RETINAL GENE THERAPY; SYRINGE; TEMPERATURE; TRANSLATIONAL RESEARCH; VITREORETINAL SURGERY; DEPENDOPARVOVIRUS; GENE TRANSFER; GENE VECTOR; GENETICS; PATHOLOGY; RETINA; RETINAL DYSTROPHIES; VIROLOGY; VIRUS CAPSID;

CAPSID; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; RETINA; RETINAL DYSTROPHIES;

EID: 84983464161     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2016.086     Document Type: Article

References (35)

1. Lipinski DM, Thake M, MacLaren RE. Clinical applications of retinal gene therapy. Prog Retin Eye Res 2013;32:22-47.
2. McClements ME, MacLaren RE. Gene therapy for retinal disease. Transl Res 2013;161:241-254.
3. Anderson WF. Prospects for human gene therapy. Science 1984;226:401-409.
4. Friedmann T. A brief history of gene therapy. Nat Genet 1992;2:93-98.
5. Vandenberghe LH, Auricchio A. Novel adenoassociated viral vectors for retinal gene therapy. Gene Ther 2012;19:162-168.
6. Day TP, Byrne LC, Schaffer DV, Flannery JG. Advances in AAV vector development for gene therapy in the retina. Adv Exp Med Biol 2014;801:687-693.
7. Petrs-Silva H, Linden R. Advances in gene therapy technologies to treat retinitis pigmentosa. Clin Ophthalmol 2014;8:127-136.
8. Jacobson SG, Cideciyan AV, Ratnakaram R, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 2012;130:9-24.
9. MacLaren RE, Groppe M, Barnard AR, et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 2014;383:1129-1137.
10. Bennett J, Chung DC, Maguire A. Gene delivery to the retina: from mouse to man. Meth Enzymol 2012;507:255-274.
11. Bennett J. Immune response following intraocular delivery of recombinant viral vectors. Gene Ther 2003;10:977-982.
12. Willett K, Bennett J. Immunology of AAVmediated gene transfer in the eye. Front Immunol 2013;4:261.
13. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 2003;3:879-889.
14. Medawar PB. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 1948;29:58-69.
15. Bennett J, Ashtari M, Wellman J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 2012;4:120ra15.
16. Treumer F, Roider J, Hillenkamp J. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage. Br J Ophthalmol 2012;96:708-713.
17. Vander JF. Tissue plasminogen activator irrigation to facilitate removal of subretinal hemorrhage during vitrectomy. Ophthalmic Surg 1992;23:361-363.
18. Kita M, Negi A, Kawano S, et al. Measurement of retinal adhesive force in the in vivo rabbit eye. Invest Ophthalmol Vis Sci 1990;31:624-628.
19. Bennicelli J, Wright JF, Komaromy A, et al. Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther 2008;16:458-465.
20. Jacobson SG, Cideciyan AV, Roman AJ, et al. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med 2015;372:1920-1926.
21. Lipinski DM, Barnard AR, Singh MS, et al. CNTF gene therapy confers lifelong neuroprotection in a mouse model of human retinitis pigmentosa. Mol Ther 2015;23:1308-1319.
22. Charbel Issa P, De Silva SR, Lipinski DM, et al. Assessment of tropism and effectiveness of new primate-derived hybrid recombinant AAV serotypes in the mouse and primate retina. PLoS One 2013;8:e60361.
23. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008;358:2240-2248.
24. Edwards TL, Jolly JK, Groppe M, et al. Visual acuity after retinal gene therapy for choroideremia. N Engl J Med 2016;374:1996-1998.
25. MacLaren RE, et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 2014;383:1129-1137.
26. Zhao YZ, Sun CZ, Lu CT, et al. Characterization and anti-tumor activity of chemical conjugation of doxorubicin in polymeric micelles (DOX-P) in vitro. Cancer Lett 2011;311:187-194.
27. Igarashi T, Miyake K, Asakawa N, et al. Direct comparison of administration routes for AAV8-mediated ocular gene therapy. Curr Eye Res 2013;38:569-577.
28. Marangoni D, Wu Z, Wiley HE, et al. Preclinical safety evaluation of a recombinant AAV8 vector for X-linked retinoschisis after intravitreal administration in rabbits. Hum Gene Ther Clin Dev 2014;25:202-211.
29. Pang J-J, Dai X, Boye SE, et al. Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa. Mol Ther 2011;19: 234-242.
30. Vandenberghe LH, Bell P, Maguire AM, et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011;3:88ra54.
31. Zhong L, Li B, Mah CS, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A 2008;105: 7827-7832.
32. Buning H, Bolyard CM, Hallek M, Bartlett JS. Modification and labeling of AAV vector particles. Methods Mol Biol 2011;807:273-300.
33. Lux K, Goerlitz N, Schlemminger S, et al. Green fluorescent protein-tagged adeno-associated virus particles allow the study of cytosolic and nuclear trafficking. J Virol 2005;79:11776-11787.
34. Perabo L, Goldnau D, White K, et al. Heparan sulfate proteoglycan binding properties of adenoassociated virus retargeting mutants and consequences for their in vivo tropism. J Virol 2006;80: 7265-7269.
35. Daya S, Berns KI. Gene therapy using adenoassociated virus vectors. Clin Microbiol Rev 2008; 21:583-593.